Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > The Private Market for Tuberculosis… >
The Private Market for Tuberculosis Drugs

Published: May 5, 2011.
By GCI Health- TB Alliance

(May 4, 2011, NEW YORK, USA) Tuberculosis (TB) is widely considered a public health concern and its treatment a public sector responsibility. But according to a study published today in the journal PLoS ONE, the private sector for TB treatment is ignored at our peril. Across 10 high-burden countries, there is as much TB drug volume in the private sector as in the public sector—and at least a third of all private sector dosages of first-line TB drugs fall outside of national and international treatment recommendations. Any resulting drug misuse could be responsible for many treatment failures and for escalating the emergence of multidrug-resistant TB (MDR-TB), which is further worsening the TB epidemic.

The research, conducted by the TB Alliance and IMS Health (a healthcare market research and consulting-services firm), is the first detailed study of the private TB drug market across multiple high-burden countries. Sixty percent of the world's TB burden is present in the 10 study countries (Bangladesh, China, India, Indonesia, Pakistan, Philippines, Russian Federation, South Africa, Thailand, and Viet Nam).

TB treatment requires lengthy, supervised treatment to maximize cure rates and minimize the development of drug resistance, and in low-income settings this task is thought to be more achievable in the public sector. By contrast, the private sector treatment landscape in these countries is largely unregulated and fragmented; for example, the study detected 111 different first-line TB drug dosages and combinations, compared to the 14 deemed necessary by the Stop TB Partnership's Global Drug Facility.

"The private sector is keeping alive the confusion that existed previously in the public sector," said Dr. William Wells, the study's lead author and Director of Market Access at the TB Alliance. "With this new baseline understanding of the TB drug market, we can no longer ignore the private sector's critical role in the access equation for TB treatment and in the task of protecting both current drugs and new regimens from the development of resistance."

Other key findings revealed that:

  • The public and private sectors are both major channels of treatment for TB patients. Nearly equal amounts of TB drugs are dispensed in the public and private sectors (enough to treat 67 percent vs. 66 percent of estimated incidence, respectively). The size of the private sector for TB drugs varies between countries, but has been steady within most countries over the past 5 years.

  • Four of the biggest high-burden countries – India, Indonesia, Pakistan, and Philippines – had particularly large private sectors. Enough TB drugs are sold in their private sectors to treat all, or nearly all, incident TB patients with a full TB drug regimen. This is without even considering the 60 to 80 percent coverage by the public sector.

  • Few patients receive MDR-TB treatment in the public sector—and the data reveal that the private sector is not stepping in to fill the gap. Private sector sales have the capacity to cover only ~1-10% of MDR-TB patients (or 0%, in three study countries) with anything approaching a full regimen. However, with new, rapid diagnostics becoming available, this market may expand rapidly, thus highlighting the urgency for action now.

"During the past decade, the world has seen a reawakening of TB drug development efforts, and the first wave of new TB treatments will be introduced within the next few years," said Dr. Mel Spigelman, President and CEO of the TB Alliance. "This study fills a critical gap in our knowledge base."

"Most countries covered in this study have public-private mix (PPM) programmes for TB care," said Mario Raviglione, Director of the Stop TB Department at the World Health Organization. "Based on country experiences, these programmes have shown good results in optimizing TB management by private care providers. However, the size of the response is not commensurate with the size of the challenge; there is enormous scope to expand these programmes urgently. Private providers following best practices should be supported through accreditation and access to free TB drugs from the public sector, while those not doing so should be regulated. Greater government and international support is needed for these efforts and also for improved regulatory oversight and quality assurance of TB drugs. A dual track approach of collaboration and regulation is the logical way forward. We ought to make private providers responsible partners of the public sector in controlling TB and MDR-TB".




Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Drug 
9/16/13 
Prescription Drug Expenses in Canada Are a Health-care Barrier
By Canadian Medical Association Journal
High drug expenses in Canada are a substantial barrier for people to access prescription drugs outside of hospital, states an analysis in CMAJ (Canadian Medical Association Journal). …
Drug 
10/24/11 
Impact of Canada's Common Drug Review on Drug Listing
By Canadian Medical Association Journal
The number of drugs covered by public drug plans decreased substantially after Canada's Common Drug Review was introduced in 2003, and new drugs were listed more quickly in several …
Surrogate 
9/13/11 
U.S. Public May Not Be Aware of Important Uncertainties About Drug Benefits And Harms
By JAMA and Archives Journals
CHICAGO – Many U.S. adults believe that only extremely effective drugs without serious adverse effects are approved, but providing explanations to patients highlighting uncertainties about drug benefits may affect …
Safety 
11/5/12 
★★★★ 
Medical Care Presents Update on Pharmaceutical Health Services Research
By Wolters Kluwer Health
Philadelphia, Pa. (November 5, 2012) - Pharmaceutical health services research goes beyond studying the effects of individual drugs, to looking at the complex and interrelated effects of medications on …
Drug 
1/5/12 
New Guideline: Caution Needed When Choosing Seizure Drugs for People with HIV/AIDS
By American Academy of Neurology
A new guideline issued by the American Academy of Neurology recommends doctors use caution when choosing seizure drugs for people with HIV/AIDS to avoid potential drug interactions. The guideline, …
Surveillance 
1/10/11 
Why We Need Better Drug Monitoring
By Canadian Medical Association Journal
The use of recombinant activated factor 7 (rFVIIa) despite its potential for adverse events displays the serious shortcomings of Canada's current drug surveillance system, according to a commentary published …
Boston 
11/1/12 
The Cost of Prescription Drugs - a Comparison of 2 Countries
By Boston University Medical Center
(Boston) - In the United States, the cost paid for statins (drugs to lower cholesterol) in people under the age of 65 who have private insurance continues to exceed …
Patients 
2/21/13 
For Embolism Patients, Clot-busting Drug Is Worth Risk
By Michigan State University
EAST LANSING, Mich. --- When doctors encounter a patient with a massive pulmonary embolism, they face a difficult choice: Is it wise to administer a drug that could save …
Eye 
6/2/14 
Choosing One Drug over Another to Treat Blindness Could Save Medicare Billions
By University of Michigan
ANN ARBOR—If all eye doctors prescribed the less expensive of two drugs to treat two common eye diseases of older adults, taxpayer-funded Medicare plans could save $18 billion over …
Law 
2/23/11 
Americans And Canadians Get Different Drug Information Online: UBC Study
By University of British Columbia
Americans and Canadians are getting vastly different search results when they look up prescription drug information online, says a study by researchers at the University of British Columbia. …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition